Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT) - Université de Lille Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2018

Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)

Lj Lazarevic Vladimir
  • Fonction : Auteur
Myriam Labopin
  • Fonction : Auteur
Depei Wu
  • Fonction : Auteur
Anne Huynh
  • Fonction : Auteur
Per Ljungman
  • Fonction : Auteur
Nicolaas Schaap
  • Fonction : Auteur
J Cornelissen Jan
  • Fonction : Auteur
Natacha Maillard
  • Fonction : Auteur
Pietro Pioltelli
  • Fonction : Auteur
Tobias Gedde-Dahl
  • Fonction : Auteur
Stig Lenhoff
  • Fonction : Auteur
Mohamed Houhou
  • Fonction : Auteur
Jordi Esteve
  • Fonction : Auteur
Mohamad Mohty
  • Fonction : Auteur
Arnon Nagler
  • Fonction : Auteur

Résumé

The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR-ABL1-positive acute myeloid leukemia (AML). Fifty-seven patients (median age, 48 years, range: 19-67) with BCR-ABL1 positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (BCR-ABL1/ABL < 104) at time of SCT in 36.1% (14/40). After SCT, 16 (61.5%) out of 26 patients with MRD positive at transplantation reached MRD negativity. After a median follow-up of 6.3 years (0.7–14.2), NRM, RI, LFS, OS, and GRFS at 5 years were 18.1%, 37%, 44.2%, 53.8%, and 32.1%, respectively. The cumulative incidence of acute GvHD grade II-IV was 16.4%, incidence of chronic GvHD 24.9%, and of extensive cGvHD 21.4%, respectively. In patients who received SCT in CR1, 5-yr NRM, RI, LFS, OS, and GRFS were 15.9%, 36.4%, 46.5%, 59.4%, and 34.9%, respectively. Univariate analysis showed that age (<50 vs. ≥50 years) was associated with RI (5-yr: 22.7 vs. 50%), LFS (5-yr: 61.9 vs. 31.8%), and GRFS (5-yr: 52.4 vs. 18.2%), whereas MRD-negative status before SCT was associated with an improved GRFS (38.9 vs. 16.7%). We conclude that the outcome of patients <50 years of age with BCR-ABL1-positive AML receiving allogeneic SCT in CR is relatively favorable, possibly reflecting the beneficial effect of the use of TKI.

Dates et versions

hal-04313964 , version 1 (29-11-2023)

Identifiants

Citer

Lj Lazarevic Vladimir, Myriam Labopin, Depei Wu, Ibrahim Yakoub-Agha, Anne Huynh, et al.. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2018, American Journal of Hematology, 93, pp.31-39. ⟨10.1002/ajh.24928⟩. ⟨hal-04313964⟩

Collections

RIIP UNIV-LILLE
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More